Imunon, Inc. Overview
Pro stress-test →Imunon is a clinical-stage biotechnology company developing DNA-mediated immunotherapies with a focus on immuno-oncology and vaccine candidates. The company's lead program, IMNN-001, is a DNA-based interleukin-12 (IL-12) immunotherapy currently in Phase 3 development (OVATION 3 trial) for advanced ovarian cancer, showing preliminary data demonstrating a median 13-month overall survival benefit.
Strategic Profile
Pro stress-test →Imunon leverages proprietary plasmid DNA technology platforms (TheraPlas and PlaCCine) to deliver cytokines and therapeutic proteins for cancer and infectious disease applications. The company is strategically positioned to address unmet needs in ovarian cancer treatment and next-generation vaccines, though it faces typical clinical-stage biotech risks including funding, trial execution, and regulatory approval hurdles.
Competitive Landscape
Pro stress-test →Imunon competes in the ovarian cancer immunotherapy space against established players and clinical-stage biotech firms developing checkpoint inhibitors and combination therapies. Key competitors include Roche/Genentech, Merck, AstraZeneca, and emerging players with similar DNA/gene therapy approaches. Imunon's differentiation lies in its DNA-mediated delivery platform, though clinical efficacy versus standard checkpoint combinations remains unproven in Phase 3.
Industry Context
Imunon, Inc. operates in Biotechnology / Immuno-Oncology.
Key facts
Founded: 1999 · Headquarters: Lawrenceville, New Jersey, US · Market cap: $15.21M